|

H1 receptor antagonist Clinical Trials

2 actively recruiting trials across 2 locations

▼ -1 trial since May 2026

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • Merck Sharp & Dohme LLC2

Indications

  • Cancer2
  • Lung Neoplasm Malignant1
  • Fallopian Tube Cancer1
  • Primary Peritoneal Cancer1
  • Ovarian Cancer1

Birmingham, Alabama1 trial

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

University of Alabama at Birmingham ( Site 0006)

Phase 3

Daphne, Alabama1 trial

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

Southern Cancer Center (SCC) ( Site 8004)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.